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Human Immunodeficiency Virus: 
Structure, Life Cycle, and 
Pathogenecity 
Jonathan Hughes 
Viruses are the smallest infectious agents of animal and plant tissues. They range 
in size from 20 to 300 nm (lnm = one billionth ofa meter). To cause a disease, viruses 
must enter living cells, unlike bacteria which are able to survive outside cells. Viruses are 
totally dependent on living cells to survive as they utilise the host cell's own replication 
processes, in order to reproduce themselves (Abbas, 2000). 
mv the causative agent of AIDS, was identified in 1983 following the first 
reported cases of Acquired Immunodeficiency Syndrome (AIDS) in 1981 and 1982. 
mv is a member of a class known as Retroviruses. These viruses store their 
genetic information as ribonucleic acid (RNA), unlike most viruses which store their 
genetic information as deoxyribonucleic acid (DNA). Before viral replication can take 
place, the RNA must be converted to DNA by reverse transcription, hence the Latin term 
Retro, meaning 'turning back' (Abbas, 2000). 
mv comprises an outer envelope consisting of a lipid bilayer with spikes of 
glycoproteins (gp), gp41 and gp120. These glycoproteins are linked in such a way that 
gp 120 protrudes from the surface of the virus. Inside this envelope is a nucleocapsid 
(p 17), which surrounds a central core of protein, p24. Within this core, are two copies of 
single-stranded RNA (the virus genome). Proteins, p7 and p9, are bound to the RNA and 
are believed to be involved in regulation of gene expression. Multiple molecules of the 
enzyme, reverse transcriptase (R T), are also found in the core. This enzyme is responsible 
for converting the viral RNA into proviral DNA (Abbas, 2000). 
my only infects certain types of cells. In general, these are cells which carry 
CD4 receptors on their surface. Some cells in the immune system have these receptors, in 
particular, T4-lymphocytes or T-helper cells. These cells are often referred to as CD4 
cells or T 4 cells. Other cells carrying the CD4 receptor include other white blood cells 
(monocytes and macrophages), glial cells in the brain, chromaffin cells in the intestines 
and Langerhans' cells in the skin (Marr, 1998). All of these cell types have been shown to 
be infected with mv. It has also been shown, however, that cells which do not bear the 
CD4 receptor may still be infected by my which raises the possibility that other cellular 
receptors for the virus may exist. 
When my comes into contact with T-Iymphocytes (CD4 cells), the spikes of 
gp120 'slot into' the CD4 receptors (like a lock and key) allowing binding of the virus to 
the host cell. Once inside the cell, the virus loses its outer envelope and its contents are 
released into the host cell's cytoplasm, the most important of which, are the viral RNA 
and reverse transcriptase. Using the viral RNA as a template, reverse transcriptase 
catalyses the production ofa single, complementary strand of DNA from nucleotides in 
the host cell (Abbas, 2000). 
DNA is constructed of units called nucleotides. Each nucleotide is made up ofa 
base (either adenine, guanine, thymine, or cytosine), a sugar and a phosphate molecule. 
The sequence in which the bases occur detennines the genetic code of the virus. RNA 
differs from DNA in that uracil replaces thymine as a base and the sugar molecule is 
different. Once the single strand of DNA has been produced, it acts as a template in the 
production of a second strand of DNA. This replication step is also catalysed by reverse 
transcriptase and the resulting double-stranded DNA is known as proviral DNA (Abbas, 
2000). This is then incorporated into the DNA of the host cell by the viral enzyme, 
integrase. It is this integration of the viral genetic material into the host cell's own genetic 
material that makes eradication of the virus, without damage to the host cell, a formidable 
goal. 
Effectively, the virus has now hijacked the host cell's own replication system. As 
a result, when the cellular DNA is transcribed, so is the viral DNA to form an RNA 
transcript. Further processing of this RNA into messenger RNA (mRNA) and genomic 
viral RNA occurs. 
The viral mRNA is then translated into viral proteins, which along with the 
genomic RNA, are assembled into new virus particles. This last stage requires the viral 
enzyme, protease (Marr, 1998). Finally, the new viral particles are released from the 
infected cell and go on to infect other cells in the body. 
Known routes ofHIV transmission include: 
• Sexual contact (homosexual, bisexual or heterosexual) 
• Contaminated needles - used for intravenous drug injection, or for general 
medical purposes In countries where disposable needles or sterilising equipment 
may be scarce 
• Vertical transmission from mother to child 
• Blood transfusions, blood products and organ/tissue transplants 
• Injuries in healthcare settings, e.g. people working with blood products, 
needlestick injuries 
(Negishi, 1993). 
There is no significant evidence to support claims that HIV may be transmitted by the 
following: 
• Insects, e.g. mosquitoes, which penetrate the skin and blood supply 
• Saliva, e.g. kissing, sharing food and eating/drinking utensils 
• Sneezing or coughing 
• Shared use of facilities and equipment, e.g. toilets, swimming pools, towels, etc 
• Casual social contact, e.g. shaking hands, hugging, etc. 
(N egishi, 1993) 
Sexual contact: 
Based on cumulative global statistics from 1983 to 1995, the World Health 
Organization estimates that 70-80 per cent of AIDS cases are transmitted through 
heterosexual contact, and five to ten per cent of cases are transmitted through homosexual 
contact. At the beginning of the epidemic, homosexual sex was perceived to be the main 
route of transmission ofHIV and accounted for the majority of known cases; however, 
heterosexual contact now accounts for the vast majority of cases of transmission. This is 
a worldwide figure, however, and it should not be forgotten that in much of Europe and 
the Americas, homosexual and intravenous drug-using populations remain the most 
affected by HIV (van Benthem, 2001). On the other hand, in sub-Saharan Africa, the 
predominant route of transmission is heterosexual. Results of a European Collaborative 
Study on heterosexual transmission from mv -infected persons to their stable 
heterosexual partners showed a cumulative transmission rate of 12.7 per cent (Marr, 
1998). Oral sex of any form is not associated with a high risk ofillV transmission, but it 
should, nevertheless, be regarded as a potential means of transmission. Genital ulceration 
has been shown to increase the risk of transmission during sexual contact as has high 
viral load in the infected person (Marr, 1998). 
The risk of sexual transmission can be decreased by a reduction in the number of 
sexual partners and the use of male and female condoms. 
Perinatal (mother-to-child) transmission: 
The World Health Organisation estimates that five to ten per cent of AIDS cases 
are caused by perinatal transmission. However, varying rates of mother-to-child 
transmission have been reported from l3 per cent in some European countries to 43 per 
cent in Kenya (although regional variations exist). There are a number of different 
possible routes of infection, including: in utero infection, during delivery and during 
breast feeding. The importance of each of these routes to the overall mother-to-child rate 
of transmission has not yet been determined. Several maternal factors appear to increase 
the risk of transmission, including high viral load and low CD4 count, particularly during 
the third trimester (Phrapradit, 1999). However, transmission has been reported across a 
wide range of maternal viral load measurements. Prematurity and low birth weight of the 
infant also appear to be associated with a higher risk of transmission. 
The risk of perinatal transmission can be reduced through giving birth by 
caesarean section and refraining from breast feeding. The use of AZT during the later 
stages of pregnancy and postnatal treatment of the neonate reduces transmission rates 
from approximately 25 per cent to 8 per cent (Sowell, 2001). 
Intravenous drug use: 
The World Health Organisation estimates that intravenous drug use is responsible 
for five to ten per cent of AIDS cases worldwide. The sharing of contaminated needles 
and syringes is the main route for viral transmission amongst intravenous drug users. 
This is believed to be an extremely 'efficient' means ofHIV transmission, as direct blood-
to-blood contact is possible. Refraining from sharing needles and syringes and the 
introduction of clean needle exchange programs can reduce the risk ofHIV transmission 
through intravenous drug use. 
Transfusions and transplants: 
The risk of transmission through transfusion and transplants is very small. The 
World Health Organisation estimates that transfusions and transplants account for only 
three to five per cent of cases. The screening/testing of all blood, blood products and 
transplant tissues, and the discouragement of blood donations from those deemed to have 
a lifestyle which may put them at increased risk of infection has significantly reduced the 
risk of transmission through these routes. 
Occupational exposure: 
Transmission ofHIV through healthcare injuries and occupational exposure is 
very rare, accounting for less than 0.0001 per cent of cases as estimated by the World 
Health Organisation. The risk of transmission from HIV -infected patients to healthcare 
workers can be reduced by the use of protective clothing, including gloves; the 
implementation or revisiting of procedures for disposing of contaminated products and 
sharp instruments; and the use of antiretroviral therapy. 
It should be noted, however, that education is potentially regarded as the most 
effective primary means of preventing infection by any mode of transmission. 
Immune Responses: 
The overall effect of infection with mv and its interaction with the body's natural 
response mechanisms is severe damage to the immune system, destroying the means by 
which the human body naturally defends itself against infections. 
Following entry into the host, mv is disseminated via the blood and circulatory 
system to different tissues in the body. From this moment of infection, the virus is 
replicating at extremely rapid rates. As the virus replicates and spreads throughout the 
body, the immune system detects the presence of the virus and mounts an immediate 
antibody response. This usually occurs within two to four weeks of infection and is 
referred to as seroconversion (because antibodies to HIV can be detected in the blood) 
(Yoshida, 2001). Early in the course of infection, mv is disseminated to the lymphoid 
tissues. The lymph system can be likened to a drainage system which filters out unwanted 
pathogens from the body and destroys them. Lymph vessels carry infectious agents to the 
lymph nodesr These nodes are located throughout the body and contain a sieve- or mesh-
like structure of follicular dendritic cells (FDCs) in their germinal centres, which trap 
bacteria, fungi, and viruses (including mV) (McMichael, 2001). The lymph nodes are 
also the site of a concentration of immune system cells, including T -lymphocytes (the 
cells which orchestrate the immune response). As the pathogens are trapped by the FDC 
network, these immune system cells attack and destroy them. 
During the earlier stages of infection, the FDC network is intact and is able to trap 
extra-cellular virions, which in combination with effective destruction of the virus by 
immune system cells results in apparently low levels of virus in other tissues as well as in 
blood and plasma. As viruses are trapped in greater concentrations, they infect the T-
lymphocytes and other cells in the lymph nodes. Gradually, more and more cells in the 
lymph nodes begin expressing my. Eventually the FDC network completely breaks 
down. This destruction of lymph node architecture has been observed in lymph node 
biopsies (Orenstein, 2000). Finally, with this complete destruction of the lymph nodes, 
viruses, bacteria, and fungi 'spill over' into the blood system and around the body. At this 
stage, levels of mv are so high that the virus is able to infect and destroy CD4 T-
lymphocytes at a faster rate than the body is able to produce new immune cells (including 
CD4 T -lymphocytes). This leaves the body unable to mount an effective immune 
response against these pathogens, including my. Eventually, clinical symptoms ofHIV 
appear, such as neurological deterioration (erg. AIDS dementia complex), as well as 
other opportunistic infections (erg. Pneumocystis carinii pneumonia) and cancers (e.g. 
Kaposi's sarcoma), indicating that the infection is in its advanced stages (Klatt, 1998). 
This entire course of events varies considerably amongst individuals but is, on average, 
approximately 12 years. 
Long-Term Non-Progressors: 
This time course of infection and disease is likely to occur in the majority of 
patients. However, a small percentage (perhaps less than five per cent) of patients are 
known to live with my infection for prolonged periods of time without experiencing 
disease progression and the appearance of symptoms. These individuals are often 
referred to as long-term non-progressors (LTNPs) and appear to have some consistent 
features of their infection: Firstly, the lymph node architecture of L TNPs is usually 
completely preserved. In addition, the proportion of lymphoid tissue occupied by 
germinal centres in the early stages of disease is significantly lower, reflecting the state of 
activation of the lymph node. Also, L TNPs appear to have consistently lower levels (by 
approximately one log) of illY RNA as compared with progressors. However, it is 
important to remember that the virus in L TNPs is still infectious and able to replicate. 
Levels of viraemia are, also, generally lower in L TNPs and may increase transiently 
without an obvious effect on the CD4 cell count. In addition, L TNPs tend to have a more 
robust immune response, with particularly high levels of neutralising antibodies. 
Although the exact reason why some individuals experience long-term non-progression is 
unclear and it is likely that they probably represent a heterogeneous group of patients 
with variable impacts from the virus and host factors (Propatio, 2001). 
The pattern and rate of progression of illY disease varies significantly between 
individuals and appears to be dependent upon the individual's age, sex, general health and 
mode of infection. 
Course of infection: 
In the 1990s, the time to development of AIDS after initial infection with the 
virus is approximately 10 to 12 years. In the mid 1980s, however, the average time from 
infection to AIDS was 8 to 10 years (Klatt, 1998). This improvement in time to 
development of AIDS is due, in part, to improved diagnosis, increased use of 
antiretroviral therapy and improved management of opportunistic infections. Although 
the clinical, virological and immunological course of lIlV infection varies, a generalised 
course of events can be determined. 
During the initial days following infection, the levels oflIlV RNA (a marker of 
lIlV infection) rise steeply, mostly due to high rates of viral replication and the resulting 
large amount of virus in the blood. Some weeks after infection, the immune system 
mounts a response to the infection, producing antibodies to lIlV, which lower the amount 
of virus in the blood. However, viral levels in the whole body still remain relatively high. 
This stage of infection, seroconversion, usually occurs between two to four weeks after 
infection, but it may take as long as six months (Ashebir, 1996). A significant drop of 
CD4 cells is also observed, which, although transient in nature, usually never fully 
returns to pre-infection levels. Clinically, patients at this stage of infection experience no 
symptoms. However, seroconversion may be characterised by a rash, fever, fatigue and 
lymphadenopathy. Following seroconversion a period of clinical latency is observed 
which may last for approximately ten years. However, this should not be mistaken for a 
period of virological and immunological latency. As previously mentioned, the levels of 
viral replication and immune cell turnover are extremely high. Whilst levels of the 
infectious virus in the peripheral blood are low during this period, higher levels are 
observed in the plasma and in specific tissues (especially lymphoid tissues). Overall, the 
level of the virus in the body is seen to rise over time. Concurrently, CD4 counts decline 
gradually during the same period. Whilst these two markers of infection are the most 
accurate determinants of the status of infection, changes in other laboratory markers are 
often observed. Typically, these include an increase in levels of p24 antigen, beta2-
micro globulin and serum neopterin; and a decrease in levels of p24 antibody 
haemoglobin, neutrophils, platelets, lymphocytes, and interleukin-2-receptors 
(Chibatamoto, 1996) . 
As the infection continues, viral load and replication rates reach such a magnitude 
that lymphoid tissues are completely destroyed and the turnover of CD4 T -lymphocytes 
can not match the destructive actions of the virus. Thus, CD4 cell counts are seen to 
decline at an increasingly faster rate and, with a weakening immune system, levels of 
viral RNA begin to increase once again. These virological and immunological events 
mark the onset of the more advanced stage of infection, characterised by the onset of 
clinical symptoms. 
At this stage of infection, viral load in individuals may be extremely high, around 
one million copies/ml, although individual variation is significant. Although CD4 cell 
counts may also vary, individuals with CD4 counts below 200 cells/mm3 are at the 
greatest risk of developing opportunistic infections (note that CD4 cell counts of healthy 
individuals are usually above 1000 cells/mm3) (Chibatamoto, 1996). 
The first clinical symptoms of this advanced stage vary considerably and include: 
persistent thrush (candidiasis, oral and genital), oral hairy leukoplakia and herpes. Other 
signs include impaired neurological function, night sweats, weight loss, fever, diarrhoea, 
malaise and fatigue (Hays, 1992). 
As this advanced stage continues, clinical diseases often increase in their severity 
and may include Kaposi's sarcoma, Pneumocystis carinii pneumonia, tuberculosis, and 
neurological dysfunction. Eventually, infected individuals reach a stage when their 
condition is classified as Acquired Immunodeficiency Syndrome. Whilst this 
classification does not make a positive contribution to patients, the staging of the disease 
course using clinical, virological, and immunological markers is very useful in the 
context of clinical trials. Survival times following a diagnosis of AIDS vary and often 
depend on the opportunistic infections that a person may have and the management 
options available. 
Categorization of AIDS: 
The CDC in Atlanta, Georgia, has developed a widely-used system by which the 
disease status ofHIV-infected adolescents and adults is categorised on the basis of 
clinical conditions associated with HIV infection and CD4 cell counts. The system 
divides CD4 cell counts into three categories: Category A consists of one or more of the 
conditions listed in the slide with documented HIV infection. Conditions in Category B 
or Category C must not have occurred. Category B consists of symptomatic conditions, 
some of which are listed in the slide, that are not included in Category Cr The clinical 
conditions must meet at least one of the following criteria: (1) the conditions are 
attributed to HIV infection or are indicative of a defect in cell-mediated immunity, (2) the 
conditions are considered by physicians to have a clinical course or to require 
management that is complicated by mv infection (CDC). 
A patient with any disease included in Category C (Cl, C2 or C3) is considered to 
have AIDS, as is any patient with a CD4 cell count of below 200 cells/mm3 . 
Opportunistic infections (Ols) are caused by organisms (bacteria, viruses, fungi, 
parasites) that the immune system would normally fight off. People with mv are 
vulnerable to infection with these organisms because of the destruction of their immune 
system. Some of the more common Ols are listed in the following slides, in addition to 
other symptoms of advanced disease. 
Skin and mouth infections and symptoms: 
• Seborrhoeic dermatitis, a type of eczema, is one of the most common infections 
and occu rs as a red, scaly rash on the face and scalp. 
• Tinea is a fungal infection which affects the feet (athlete'S foot) and groin. 
• Candida albicans is a fungus which can cause thrush in the mouth, vagina, or 
oesophagusr 
• Oral hairy leukoplakia is white, warty-like growths on the sides ofthe tongue and 
cheeks and is usually painless, although its appearance worries many individuals. 
It is caused by Epstein Barr virus. 
• Impetigo is an irritating and contagious bacterial skin infection 
• Herpes simplex virus is sexually transmitted and symptoms may range from mild 
irritation in genital and anal areas to painful, deep ulcers. 
• Varicella zoster virus causes shingles, which, if it becomes widespread 
throughout the body, can be fatal. 
• Kaposi's sarcoma is a cancer which is diagnostic of AIDS. It frequently occurs as 
raised purplish patches on the skin. A herpes-like virus has been implicated in the 
development of Kaposi's sarcomar 
(Schneider, 2000). 
Effects on the nervous system: 
A wide spectrum of neurological complications affecting each part of the nervous 
system has been described in mv -infected individuals. These include otherwise rare 
opportunistic infections and neoplastic diseases, such as cerebral toxoplasmosis, 
cryptococcal meningitis and primary central nervous system (CNS) lymphoma, as well as 
syndromes caused by or directly related to, mv infection, such as dementia and various 
neuromuscular complications (Krebs, 2000). Today, at least 70 per cent ofmV-infected 
individuals exhibit some type of neurological complication, and neuropathological 
abnormalities are found in 80 to 90 per cent of patients at autopsy (Krebs, 2000). 
mv was first isolated from the brain and cerebrospinal fluid of people with AIDS 
with neurological disorders in 1985. Whilst it is now generally accepted that mv 
infection of the brain results in the clinical syndrome known as AIDS dementia complex 
(ADC), many questions about the pathogenesis of ADC remain unanswered. There is 
evidence that the virus infects the brain early in infection but that the neurones 
themselves are rarely infected 0JVesselingh, 2001). This presents an intriguing paradox-
how does mv cause disease in the brain? The answer seems to lie in a combination of 
direct and indirect effects ofillV on cells of the CNS. 
• AIDS dementia complex (ADC) is an AIDS defining illness characterised by 
symptoms including slowed thought, impaired concentration, memory deficit, 
confusion, clumsiness, loss of co-ordination, tremor, inability to walk, 
incontinence, social withdrawal, noticeable change in personality and irrational 
behaviour. Since the introduction of AZT in 1987, the incidence of ADC has been 
greatly reduced, from approximately 53 per cent to 10 per cent in one study I J. 
Further studies have confirmed the therapeutic efficacy of zidovudine in the 
treatment of ADC. It is apparent that no other antiretroviral agents have 
demonstrated comparable efficacy and safety to AZT in preventing and reversing 
the effects of ADC. 
• Peripheral neuropathy (destruction of nerve tissue) occurs in 10 to 15 per cent of 
individuals with AIDS. It can cause severe pain in the legs, feet and extremities. 
• Cryptococcus neoformans, a common fungi found in soil, is a recognised cause of 
meningitis. It can also cause generalised infection in the body which is life-
threatening in approximately ten per cent of individuals with AIDS. 
• Toxoplasma gondii, a protozoal parasite, causes toxoplasmosis of the brain, a 
condition which is associated with headache, confusion, personality changes and 
seizures and can result in coma and death. 
• Cytomegalovirus is often associated with retinitis which can lead to blindness and 
may also be associated with neurological illnesses, including encephalitis 
(inflammation of the brain). 
• Lymphoma (a tumour of the lymphoid tissue) can occur in the brain, causing 
headaches, confusion, seizures, and problems with vision. 
(Tardieu, 1999). 
Other Systems Affected: 
Effects on the respiratory system: 
• Pneumocystis carinii pneumonia (PCP) was the most common 01 in people with 
AIDS. Prophylaxis of PCP has drastically reduced the incidence of this infection 
from around 60 per cent of patients with AIDS in the USA in the mid 1980s to 
around 5 per cent today. Symptoms of PCP include a dry cough, shortness of 
breath, and sometimes, pneumonitis, making breathing painful. 
• Tuberculosis (TB) is caused by the bacterium Mycobacterium tuberculosis. Many 
countries have seen a rise in the number of cases of TB, with the increasing 
incidence ofHIV infection. Drug-resistant strains of TB are becoming a 
significant worldwide problem as many patients do not take their full course of 
therapy. This infection, unlike many others associated with mv, is infectious to 
all individuals. This infection flourishes in conditions of deprivation and 
overcrowding. It is endemic in many developing countries. 
• Mycobacterium avium intracellulare occurs in approximately 50 per cent of 
individuals who have low CD4 counts. Symptoms are generally non-specific and 
include fever, weight loss, anaemia, enlarged liver and chronic diarrhoea. 
• Bronchitis and pneumonia, caused by a variety of bacteria, occur more often in 
people with mv 
• Kaposi's sarcoma and other cancers are often the cause of lung complaints in 
people with AIDS. 
(de Leon, 1995). 
Effects on the gastrointestinal (GI) system: 
• Candida albicans (thrush) is one of the early signs that the immune system is 
• 
• 
faltering. It often infects the oesophagus and causes pain and difficulty when 
swallowing. 
Herpesvirus infections can cause inflammation and ulceration all along the GI 
tract, from the mouth to the anus. 
Cryptosporidium muris and microsporidium are protozoa whi h fr 
care equently the 
cause of severe diarrhoea. 
• Kaposi's sarcoma of the GI tract is found in many people who die of AIDS. 
(Knox, 2000). 
Cancers: 
• Kaposi's sarcoma is a malignant, life-threatening cancer of the blood vessels 
which occurs initially as flat, purplish patches on the skin. The cancer may, 
however, affect any part of the body, and young male homosexuals appear to be 
most vulnerable to this cancer. A herpes-like virus has been implicated in the 
development ofKarposi's sarcoma. 
• Non-Hodgkin's lymphoma (NHL) is a life-threatening cancer for people with 
advanced mv infection and is increasing in incidence. Around 30 per cent of 
mY-infected individuals with NHL have some involvement of the brain. 
• Other cancers have been noted in people with mv and AIDS, including rectal 
cancer, head and neck cancer and melanoma. 
(Clarke, 2001). 
mv Screening: 
Most of the currently used first-line screening systems to diagnose HIV infection 
employ enzyme-linked immunosorbent assay (ELISA) techniques. These assays detect 
the presence of antibodies to mv in blood samples (although kits are now available to 
test urine and saliva samples) (Kosko, 2000). Automated processing of multiple samples 
using microwell plates enables large-volume throughput, essential to the screening of 
blood donations. Combination assays for detecting both mv 1 and mv 2 ft 
- - are 0 en used 
in countries where both strains may be prevalent. The use of these combined assays is 
increasing worldwide. 
If any samples are found to be positive in the first-line screening procedure, 
further confirmatory tests are required to ensure that the initial results are not inaccurate, 
so-called 'false positives'. Currently, many laboratories use Western Blot technique 
(antibody reaction to viral proteins and glycoproteins) as a second line testing procedure. 
A positive result generally requires the presence of bands correlating to p24, p31, gp41, 
and gp120 or gp160 (Roberts, 1994). 
One weakness of these methodologies is that they measure the presence of antibodies 
to illV rather than the presence of the viral components themselves. lt is, therefore, 
possible that infection may not be diagnosed in individuals who have not yet developed 
an antibody response to the virus. 
A number of other techniques have been developed and refined in recent years to 
enable the accurate monitoring ofillV over the course of infection. These include: 
Polymerase chain reaction (PCR) : 
This technology is able to detect the presence of viral genetic material (both RNA 
and DNA) and involves three distinct steps: denaturation, annealing, and polymerisation. 
Repeated cycles of this process produce microgram quantities of viral DNA or RNA. 
This methodology has been developed further, with the inclusion of internal standards in 
commercially available kits (known quantities of genetic material) to allow accurate 
quantification of viral RNAIDNA. In addition, this technology has been automated to 
allow high-volume processing of numerous samples (Klatt, 1998). 
Branched-chain DNA (b-DNA) : 
This approach differs from other assays in that it is based on signal amplification 
rather than target amplification. Quantitation is determined by comparing the 
chemiluminescence of samples with a four -point standard curve assayed in each 
microwell plate (Klatt, 1998). 
Nucleic acid sequence-based amplification (NASBA) : 
This technology involves isolation by lysis and binding to silicon dioxide 
particles, followed by an isothermal amplification procedure. Three levels of calibration, 
or internal standards, are included and detection is based on an enzyme-linked gel assay 
or electro chemiluminescence (Kosko, 2000). 
These technologies have made it possible to quantitatively measure plasma viral 
levels in individuals, from which, disease status and risk of disease progression can then 
be determined. 
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